
VIP-3651
CDX-101 | Astaxanthin Prodrug NCE
Astaxanthin dimethylglycine diester prodrug, its salts and compositions, and therapeutic uses—an anti-inflammatory pipeline in a pill.
This portfolio centers on US Patent 12,338,209 B2, which covers CDX-101, a new oral form of astaxanthin. CDX-101 is a prodrug: astaxanthin joined to N,N-dimethylglycine, designed to release astaxanthin once taken. Astaxanthin is a strong antioxidant that, in cell and animal studies, also acts early in the inflammatory process through the NF-κB and Keap1-Nrf2 pathways. Docking studies suggest it binds Keap1 directly, which has not yet been confirmed experimentally.
Astaxanthin is hard to formulate and poorly absorbed, and earlier amino acid prodrugs needed extra protection and deprotection steps to make. CDX-101 is made in a single step and purified by simple recrystallization.
The granted claims cover the compound itself and its salts (composition of matter), compositions that stay at least 90 percent intact after a week at room temperature, and methods of preventing or treating cardiovascular disease by lowering C-reactive protein in patients already on standard care. The patent was granted in June 2025 with 728 days of term adjustment, and its anticipated expiration is September 23, 2042, subject to maintenance fees.
CDX-101 is a pre-clinical asset and has not yet been tested in humans, but the astaxanthin it releases has an extensive human record: more than 4,600 published studies, including roughly 90 to 100 clinical trials and a 2020 European Food Safety Authority finding that 8 mg per day is safe for adults.
The seller also reports an unpublished, randomized, double-blind, placebo-controlled pilot in 40 patients on standard care, in which 12 weeks of astaxanthin significantly lowered LDL cholesterol, total cholesterol, oxidized LDL, blood pressure, and in a prespecified diabetic sub-group (25 subjects), hsCRP. These pilot human studies provide human proof-of-concept data rarely available in pre-clinical assets. As another point of differentiation, the seller sees the safety record as a key advantage of CDX-101 over other anti-inflammatory drugs and drug candidates. In addition, this safety data may help lower the cost of early development, although studies of CDX-101 itself would still be needed.
Potential applications include oral treatment of residual inflammatory risk in cardiovascular patients, use alongside statins and other lipid-lowering drugs, and broader metabolic, liver, cognitive and musculoskeletal indications.
The patent and associated assets are available for sale, license, or joint development.
The IP and assets available for sale, license, or joint development include:
• US12338209 – “Astaxanthin esters and methods of use thereof”
• Associated file histories, and the expired background carotenoid-analog estate listed in the Patent Portfolio Summary
Other Public Data Room Materials Available Upon Request
Pricing guidance for this transaction may be available. All parties interested in the IP above are authorized to contact Charlette Hunter at Vibrant IP, LLC at charlette@vibrantip.com and +1 404-482-3652.
